68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with
prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to
a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for
'prostate specific membrane antigen'. Diagnostic procedures, such as 68GA-PSMA-11 PET
imaging, may help measure a patient's response to earlier treatment, and may help plan the
best treatment for prostate cancer.